GSK (LON: GSK) shares are up on Tuesday following news that the pharmaceutical group has agreed to acquire a T cell-engager (TCE) programme for multiple myeloma from privately held Chimagen Biosciences.
The stock traded around 1,869p, up roughly 0.8% from the previous close of 1,854.5p, as investors weighed the deal’s modest near-term financial impact against its strategic fit with GSK’s oncology ambitions.
Under the agreement, GSK will pay an upfront fee for full global rights to the trispecific TCE, with Chimagen eligible for additional development and commercial milestones. The deal carries a total potential value of up to $750 million, a figure small enough relative to GSK’s market capitalisation that it appears to have triggered only a modest positive reaction rather than a significant re-rating.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The asset, designed to target T cells and two tumour-associated antigens simultaneously, is intended to offer better efficacy and tolerability than existing TCEs in multiple myeloma, a blood cancer market forecast to exceed $10 billion in the US by 2032. The programme is expected to enter phase I trials in 2027, meaning any commercial payoff remains years away.
The transaction extends GSK’s existing relationship with Chimagen, following an earlier deal for CMG1A46, a dual CD19/CD20 TCE already in clinical trials. For now, the market’s muted but positive response suggests investors see the acquisition as a sensible, low-risk addition to GSK’s blood cancer pipeline rather than a transformative catalyst for the shares.
